SINGLE CELL TECHNOLOGIES APPLIED FOR COVID ANTIBODY AND VACCINE DEVELOPMENT
Prof.dr.ir. Leon Terstappen
Recorded during: The 2020 TechMed Event | more info
Date recording: 10 September 2020
Abstract
To discover the optimal treatment for cancer patients a technology is being developed in which the secretome of individual cancer cells can be assessed and the response to drugs evaluated. While research is being conducted at MCBP, the UT start-up VyCAP is developing and commercializing the technology. The same technology can be applied for COVID-19 in which B-lymphocytes from patients are isolated and probed for the production of anti-covid antibodies. The ability to isolate the cells producing the desired antibodies enables the unique opportunity to produce a cell line optimized for the production of anti-covid therapies.